Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Stock Has Consensus Price Target of $33.33 According to Brokerages

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) has earned an average rating of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $33.33.

CRVS has been the subject of several research reports. Weiss Ratings raised Corvus Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 28th. LADENBURG THALM/SH SH raised Corvus Pharmaceuticals to a “strong-buy” rating in a report on Thursday, July 30th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Wednesday, September 16th.

Institutional Trading of Corvus Pharmaceuticals

Large investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Corvus Pharmaceuticals in the 2nd quarter valued at about $106,654,000. Commodore Capital LP purchased a new stake in shares of Corvus Pharmaceuticals during the 1st quarter valued at $33,045,000. Perceptive Advisors LLC raised its position in shares of Corvus Pharmaceuticals by 231.1% in the 1st quarter. Perceptive Advisors LLC now owns 2,292,441 shares of the company’s stock worth $33,538,000 after buying an additional 1,600,000 shares during the period. Bank of America Corp DE acquired a new position in Corvus Pharmaceuticals in the second quarter valued at $11,322,000. Finally, Emerald Advisers LLC acquired a new position in Corvus Pharmaceuticals in the first quarter valued at $10,039,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Price Performance

NASDAQ:CRVS opened at $10.53 on Friday. The firm’s fifty day simple moving average is $12.38 and its 200-day simple moving average is $13.41. The stock has a market cap of $885.78 million, a PE ratio of -17.26 and a beta of 1.44. Corvus Pharmaceuticals has a fifty-two week low of $6.39 and a fifty-two week high of $26.95.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.03). Equities analysts anticipate that Corvus Pharmaceuticals will post -0.79 earnings per share for the current year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that harness the immune system to treat cancer. The company’s research centers on therapies designed to modulate immune-cell activity and address diseases with significant unmet medical needs.

Corvus’ leading product candidate is soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of inducible T-cell kinase (ITK). The company is studying soquelitinib as a potential treatment for T-cell malignancies, including peripheral T-cell lymphoma.